No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
CRSP241213C58000
- 0.20
- +0.13+185.71%
15min DelayTrading Dec 11 09:56 ET
0.20High0.20Low
0.20Open0.07Pre Close2 Volume119 Open Interest58.00Strike Price40.00Turnover170.79%IV21.20%PremiumDec 13, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type0.0758Delta0.0231Gamma240.10Leverage Ratio-0.1659Theta0.0002Rho18.21Eff Leverage0.0052Vega
Intraday
- 5D
- Daily
News
Is CRISPR Therapeutics AG (CRSP) the Worst ARK Stock to Buy According to Short Sellers?
Chardan Capital Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $94
Evercore Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $60
Crispr Therapeutics AG (CRSP) Gets a Hold From Evercore ISI
Analysts Are Bullish on Top Healthcare Stocks: Crispr Therapeutics AG (CRSP), Silence Therapeutics (SLN)
Chardan Capital Maintains Buy on CRISPR Therapeutics, Maintains $94 Price Target